Dr. Jason Mouabbi, Dr. Irene Kang, and Dr. Ruemu Birhiray – Beyond pCR and Toward Brain Protection

Achieving pCR has long been considered the “holy grail” in HER2+ breast cancer — but does it truly guarantee protection from recurrence, especially in the brain?

In this conversation, Drs. Jason Mouabbi, Irene Kang, and Ruemu Birhiray explore evolving perspectives on pCR, CNS relapse, and the emerging role of neratinib in protecting high-risk patients. They discuss new data, the unmet need for CNS-active strategies, and how upcoming trials like DESTINY-Breast05 and COMPASS-HER2 RD could redefine the adjuvant landscape.

Watch to understand what’s next for HER2+ disease — and how oncologists are rethinking long-term protection beyond pathologic complete response.